Combined OLA1 and CLEC3B Gene Is a Prognostic Signature for Hepatocellular Carcinoma and Impact Tumor Progression

Overview

Journal Technol Cancer Res Treat

Specialties Biomedical Engineering
Oncology
Pharmacology

Date 2024 Apr 2

PMID 38564315

Authors

Zhoufeng Chen

Liuwei Zeng

Zhuoyan Chen

Jun Xu

Xiangting Zhang

Huiya Ying

Yuan Zeng

Fujun Yu

Affiliations

Soon will be listed here.

Abstract

Hepatocellular carcinoma (HCC), partly because of its complexity and high heterogeneity, has a poor prognosis and an extremely high mortality rate. In this study, mRNA sequencing expression profiles and relevant clinical data of HCC patients were gathered from different public databases. Kaplan-Meier survival curves as well as ROC curves validated that OLA1|CLEC3B was an independent predictor with better predictive capability of HCC prognosis compared to OLA1 and CLEC3B separately. Further, the cell transfection experiment verified that knockdown of OLA1 inhibited cell proliferation, facilitated apoptosis, and improved sensitivity of HCC cells to gemcitabine. In this study, the prognostic model of HCC composed of OLA1/CLEC3B genes was constructed and verified, and the prediction ability was favorable. A higher level of OLA1 along with a lower level of CEC3B is a sign of poor prognosis in HCC. We revealed a novel gene pair OLA1|CLEC3B overexpressed in HCC patients, which may serve as a promising independent predictor of HCC survival and an approach for innovative diagnostic and therapeutic strategies.

References

Telford E, Jiang W, Martin T . HAVcR-1 involvement in cancer progression. Histol Histopathol. 2016; 32(2):121-128. DOI: 10.14670/HH-11-817. View

Balachandran V, Gonen M, Smith J, DeMatteo R . Nomograms in oncology: more than meets the eye. Lancet Oncol. 2015; 16(4):e173-80. PMC: 4465353. DOI: 10.1016/S1470-2045(14)71116-7. View

Looi M, Karsani S, Abdul Rahman M, Mohd Dali A, Md Ali S, Wan Ngah W . Plasma proteome analysis of cervical intraepithelial neoplasia and cervical squamous cell carcinoma. J Biosci. 2010; 34(6):917-25. DOI: 10.1007/s12038-009-0106-3. View

Lu C, Rong D, Zhang B, Zheng W, Wang X, Chen Z . Current perspectives on the immunosuppressive tumor microenvironment in hepatocellular carcinoma: challenges and opportunities. Mol Cancer. 2019; 18(1):130. PMC: 6714090. DOI: 10.1186/s12943-019-1047-6. View

Singh S, Banerjee S, Acosta E, Lillard J, Singh R . Resveratrol induces cell cycle arrest and apoptosis with docetaxel in prostate cancer cells via a p53/ p21WAF1/CIP1 and p27KIP1 pathway. Oncotarget. 2017; 8(10):17216-17228. PMC: 5370034. DOI: 10.18632/oncotarget.15303. View

Mishra S, Lin C, Huang T, Bouamar H, Sun L . MicroRNA-21 inhibits p57Kip2 expression in prostate cancer. Mol Cancer. 2014; 13:212. PMC: 4168249. DOI: 10.1186/1476-4598-13-212. View

Li X, Ma X, Tian F, Wu F, Zhang J, Zeng W . Downregulation of CCNA2 disturbs trophoblast migration, proliferation, and apoptosis during the pathogenesis of recurrent miscarriage. Am J Reprod Immunol. 2019; 82(1):e13144. DOI: 10.1111/aji.13144. View

Gong Z, Zhang J, Guo W . Tumor purity as a prognosis and immunotherapy relevant feature in gastric cancer. Cancer Med. 2020; 9(23):9052-9063. PMC: 7724479. DOI: 10.1002/cam4.3505. View

Sun H, Luo X, Montalbano J, Jin W, Shi J, Sheikh M . DOC45, a novel DNA damage-regulated nucleocytoplasmic ATPase that is overexpressed in multiple human malignancies. Mol Cancer Res. 2010; 8(1):57-66. DOI: 10.1158/1541-7786.MCR-09-0278. View

10.

Shen T, Huang S . The role of Cdc25A in the regulation of cell proliferation and apoptosis. Anticancer Agents Med Chem. 2012; 12(6):631-9. PMC: 3544488. DOI: 10.2174/187152012800617678. View

11.

Yao H, Lu F, Shao Y . The E2F family as potential biomarkers and therapeutic targets in colon cancer. PeerJ. 2020; 8:e8562. PMC: 7035869. DOI: 10.7717/peerj.8562. View

12.

Huang S, Zhang C, Sun C, Hou Y, Zhang Y, Tam N . Obg-like ATPase 1 (OLA1) overexpression predicts poor prognosis and promotes tumor progression by regulating P21/CDK2 in hepatocellular carcinoma. Aging (Albany NY). 2020; 12(3):3025-3041. PMC: 7041778. DOI: 10.18632/aging.102797. View

13.

Diamond M, Kinder M, Matsushita H, Mashayekhi M, Dunn G, Archambault J . Type I interferon is selectively required by dendritic cells for immune rejection of tumors. J Exp Med. 2011; 208(10):1989-2003. PMC: 3182061. DOI: 10.1084/jem.20101158. View

14.

Gonzalez L, Nebreda A . RINGO/Speedy proteins, a family of non-canonical activators of CDK1 and CDK2. Semin Cell Dev Biol. 2020; 107:21-27. DOI: 10.1016/j.semcdb.2020.03.010. View

15.

Feng Q, Lu H, Wu L . Identification of M2-like macrophage-related signature for predicting the prognosis, ecosystem and immunotherapy response in hepatocellular carcinoma. PLoS One. 2023; 18(9):e0291645. PMC: 10508629. DOI: 10.1371/journal.pone.0291645. View

16.

Li T, Kang G, Wang T, Huang H . Tumor angiogenesis and anti-angiogenic gene therapy for cancer. Oncol Lett. 2018; 16(1):687-702. PMC: 6019900. DOI: 10.3892/ol.2018.8733. View

17.

Nakayama K, Nakayama K . Ubiquitin ligases: cell-cycle control and cancer. Nat Rev Cancer. 2006; 6(5):369-81. DOI: 10.1038/nrc1881. View

18.

Yoshino Y, Qi H, Fujita H, Shirota M, Abe S, Komiyama Y . BRCA1-Interacting Protein OLA1 Requires Interaction with BARD1 to Regulate Centrosome Number. Mol Cancer Res. 2018; 16(10):1499-1511. DOI: 10.1158/1541-7786.MCR-18-0269. View

19.

Pineda C, Ramanathan S, Fon Tacer K, Weon J, Potts M, Ou Y . Degradation of AMPK by a cancer-specific ubiquitin ligase. Cell. 2015; 160(4):715-728. PMC: 5629913. DOI: 10.1016/j.cell.2015.01.034. View

20.

Zhang J, Rubio V, Lieberman M, Shi Z . OLA1, an Obg-like ATPase, suppresses antioxidant response via nontranscriptional mechanisms. Proc Natl Acad Sci U S A. 2009; 106(36):15356-61. PMC: 2741255. DOI: 10.1073/pnas.0907213106. View